In the JMIL-only population , no significant OS difference observed between treatment arms ( adjusted HR = @ -LSB- @ % CI : @-@ @ , p = @ -RSB- ; unadjusted HR = @ -LSB- @ % CI : @-@ @ , p = @ -RSB- ) , nor for other secondary efficacy endpoints .